Clovis Oncology Inc. (CLVS) saw its loss narrow to $65.70 million, or $1.70 a share for the quarter ended Sep. 30, 2016. In the previous year period, the company reported a loss of $98.64 million, or $2.62 a share. On the other hand, adjusted net loss for the quarter narrowed to $65.70 million, or $1.70 a share from a loss of $98.64 million or $2.62 a share, a year ago.
The company has not recorded any revenues for the current as well as previous quarter.
Operating loss for the quarter was $64 million, compared with an operating loss of $97.25 million in the previous year period.
"We are actively preparing for a U.S. launch of rucaparib pending FDA’s decision on our NDA, and we have completed our Marketing Authorization Application submission seeking European approval for rucaparib," said Patrick J. Mahaffy, President and CEO of Clovis Oncology. "Importantly, we remain focused on exploring rucaparib more broadly, and expect several studies to initiate this quarter, including the TRITON2 study in prostate cancer, the ARIEL4 confirmatory study in ovarian cancer and investigator-sponsored studies exploring rucaparib as maintenance therapy in gastroesophageal cancer and also in combination with bevacizumab in ovarian cancer."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: editor@irisindia.net
